Testosterone Heart Attack

Published on February 21, 2014 by Sandy Liebhard

Text-Size:A A A+

Concerns about the alleged potential for a “Low T” prescription therapy like AndroGel to cause a testosterone heart attack or stroke are continuing to rise, amidst recent research lending evidence to the association. In January 2014, the U.S. Food and Drug Administration (FDA) issued a public health alert vowing to conduct a safety review of the medications, despite no confirmed connection between certain treatments and the risk for sudden cardiac death, cardiovascular arrest and other serious heart events.

The attorneys at Bernstein Liebhard LLP are actively investigating potential claims from men who may have experienced a testosterone stroke or heart attack after taking AndroGel or another prescription treatment therapy. Those who may have suffered these life-threatening side effects are being urged to contact the Firm today for free and confidential case evaluations.

 Testosterone Heart Attack

Since the end of 2013, a number of studies have raised awareness on dangers that may be associated with certain “Low T” therapies. Our Firm’s legal staff is actively seeking testosterone stroke and heart attack lawsuits on behalf of individuals who were prescribed these medications, which are designed to raise levels of testosterone in men with low levels of the hormone.

  • AndroGel
  • Axiron
  • Androderm
  • Depo-Testosterone
  • Striant
  • Bio-T-Gel
  • Delatestryl
  • Fortesta
  • Testopel

Scrutiny surrounding these prescription testosterone treatment options reached new heights in November when the Journal of the American Medical System published the findings of a study suggesting that older men with pre-existing heart problems were at an increased risk for experiencing a testosterone stroke, heart attack and/or death.

A doubled heart attack risk was found two months later in research released by the medical journal, PLoS One. According to findings published in January 2014, younger men with pre-existing heart problems and all men older than 65 were shown to be at a doubled risk for heart attack after taking “Low T” treatments.

Testosterone Stroke

On January 31, 2014, the FDA issued a Drug Safety Communication that underlined its commitment to investigating the risk for testosterone stroke, deep vein thrombosis, and other cardiovascular side effects allegedly associated with “Low T” treatments. Court documents indicate that in the weeks following the FDA’s public health alert, a number of AndroGel lawsuits were filed in the U.S. District Court, Northern District of Illinois. In a case filed on February 4th for example, the medication’s manufacturer was accused of marketing its product to men who may be experiencing symptoms normally associated with aging, like fatigue and low libido. Testosterone lawsuits further allege that AndroGel and other medications were promoted for use in men with normal testosterone levels, even though the FDA has only approved these treatments for men who may be experiencing reduced levels of the hormone because of an underlying medical condition.

In a case filed on February 10th, the plaintiff allegedly experienced pulmonary embolism and deep vein thrombosis after taking multiple doses of AndroGel, which the complaint alleges may thicken the blood and cause hematocrit levels to increase. In turn, this may lead to cardiovascular injuries.

Filing a Testosterone Heart Attack Lawsuit

If you or a loved one suffered a testosterone heart attack after taking AndroGel or another drug, call our Firm today. You may be eligible to receive compensation for out-of-pocket medical expenses, lost wages and other damages caused by your situation. Call us today at .